Helio Genomics Appoints Dr Bharat Tewarie As Chief Executive Officer To Lead The Next Phase Of Growth In AI-Powered Cancer Detection

Justin Li to Continue as President

IRVINE, Calif., July 23, 2025 /PRNewswire/ -- Helio Genomics ("Helio" or "the Company"), a trailblazer in AI-powered, blood-based cancer diagnostics, has appointed Dr. Bharat Tewarie as its new Chief Executive Officer.

Dr. Tewarie brings decades of global healthcare leadership experience, with deep understanding of commercial, operational, and scientific levers critical to scaling innovative diagnostics platforms and delivering life-saving solutions worldwide.

Justin Li, who has served as CEO since 2021, will remain with the company as President, continuing to shape Helio's long-term strategy, partnerships, and innovation initiatives.

"Leading Helio through its growth journey has been the honor of a lifetime. I'm excited to welcome Bharat, whose deep expertise and bold vision will be valuable as we enter our next chapter." said Mr. Li.

Dr. Tewarie joins Helio with an extensive background in life sciences, including executive leadership roles across BioPharma, Digital Health, Diagnostics and Medical Devices. He has held senior positions at UCB (EVP & CMO), Merck KGaA, EMD Serono, Roche, and Boehringer Ingelheim, and served as CEO of startups including Neurocast and Prana BioSciences. Beyond his operational and commercial expertise, Bharat is passionate about the intersection of AI and data science in healthcare.

"I am honored to join Helio and accelerate its growth as our AI-driven diagnostics have the potential to redefine global cancer care. Together, we will bring innovative solutions to more healthcare providers and patients to detect liver cancer early and hence save lives." said Dr. Tewarie.

"We thank Justin for his valuable contributions and look forward to partnering with him as President. We are excited to welcome Dr. Tewarie, as we believe that under his leadership, the company is poised to accelerate its growth and advance its vision of transforming cancer outcomes." said Terry Belmont, Chairman of the Nomination Committee.

"Helio Genomics has made remarkable progress in advancing a clinically validated platform for early cancer detection," said Sunwoo, Portfolio Manager at QUAD Investment Management. "With Bharat's proven track record of scaling life sciences businesses globally, the company is well-positioned to deliver meaningful value for both patients and shareholders."

This leadership transition reflects Helio's continued commitment to scientific excellence, commercial execution, and improving patient outcomes through AI-powered solutions.

About Helio Genomics
Helio Genomics is a commercial stage, AI-driven healthcare company specializing in diagnostics technology to pioneer cancer early detection and minimal residual disease monitoring. Helio Genomics' advanced blood-based multi-analyte platform uses machine learning and deep learning to detect cancer biomarkers with unprecedented accuracy, empowering clinicians and patients to act swiftly in the fight against liver cancer. This technology has been clinically validated in studies with thousands of patients and is supported by an expanding commercial presence.

About HelioLiver Dx
HelioLiver Dx is a multi-analyte blood test that analyzes methylation patterns through cfDNA, serum protein markers and demographic information to detect early-stage HCC for patients at risk due to liver cirrhosis or Hepatitis B. HelioLiver Dx achieved superior sensitivity and non-inferior specificity compared to ultrasound, the current standard of care for HCC surveillance, as demonstrated by the results of the ENCORE and CLiMB clinical trials. HelioLiver has received a Category I Current Procedural Terminology Proprietary Laboratory Analyses, or CPT PLA, code from the American Medical Association, effective October 1, 2022, which establishes a reimbursement pathway and facilitates expected Medicare coverage for increased access and potential broader adoption of HelioLiver in the United States. HelioLiver is commercially available in the United States in a CLIA laboratory as a laboratory developed test, or LDT.

View original content to download multimedia:https://www.prnewswire.com/news-releases/helio-genomics-appoints-dr-bharat-tewarie-as-chief-executive-officer-to-lead-the-next-phase-of-growth-in-ai-powered-cancer-detection-302511449.html

SOURCE Helio Genomics